MS

Immunic's lead MS drug hits primary and key secondary endpoints in PhII, but questions remain
Immunic's lead MS drug hits primary and key secondary endpoints in PhII, but questions remain
Endpoints
Immunic
MS
multiple sclerosis
clinical trials
IMU-838
Flag link:
Biogen points to COVID-19 for disappointing drug launch
Biogen points to COVID-19 for disappointing drug launch
BioPharma Dive
Biogen
Vumerity
MS
multiple sclerosis
Flag link:
Roche, PicnicHealth start RWD partnership with multiple sclerosis focus
Roche, PicnicHealth start RWD partnership with multiple sclerosis focus
MedCity News
Roche
PicnicHealth
MS
multiple sclerosis
RWD
real world data
artificial intelligence
Flag link:
Bristol Myers Pays Dragonfly $55M to Bring NK Cells to Neuro Diseases
Bristol Myers Pays Dragonfly $55M to Bring NK Cells to Neuro Diseases
Xconomy
Bristol-Meyers Squibb
Dragonfly Therapeutics
multiple sclerosis
MS
neuroinflammation
Flag link:
Mylan, looking to capitalize on Biogen's Tecfidera patent loss, faces fork in the road on generic launch
Mylan, looking to capitalize on Biogen's Tecfidera patent loss, faces fork in the road on generic launch
Fierce Pharma
Biogen
Tecfidera
Mylan
patents
generics
MS
multiple sclerosis
Flag link:
Judge wipes out Biogen's Tecfidera patent protections in suit against Mylan
Judge wipes out Biogen's Tecfidera patent protections in suit against Mylan
Fierce Pharma
Biogen
Mylan
Tecfidera
patents
MS
multiple sclerosis
Flag link:
Bristol Myers Squibb's Zeposia launches into crowded MS market
Bristol Myers Squibb's Zeposia launches into crowded MS market
Fierce Pharma
Bristol-Myers Squibb
Celgene
Zeposia
drug launches
MS
multiple sclerosis
Flag link:
Novartis builds case for MS drug ofatumumab as FDA decision looms
Novartis builds case for MS drug ofatumumab as FDA decision looms
Pharmaforum
Novartis
ofatumumab
clinical trials
MS
multiple sclerosis
Flag link:
Sanofi posts data from contentious phase 2 multiple sclerosis trial
Sanofi posts data from contentious phase 2 multiple sclerosis trial
Fierce Biotech
Sanofi
clinical trials
MS
multiple sclerosis
Principia Biopharma
SAR442168
Flag link:
Early treatment with Novartis' Mayzent stalls secondary progressive MS: study
Early treatment with Novartis' Mayzent stalls secondary progressive MS: study
Fierce Pharma
Novartis
Mayzent
MS
multiple sclerosis
Gilenya
Flag link:
FDA Approves Bristol Myers MS Drug, But Pandemic Will Delay Launch
FDA Approves Bristol Myers MS Drug, But Pandemic Will Delay Launch
Xconomy
Bristol-Meyers Squibb
Celgene
M&A
ozanimod
MS
mutliple sclerosis
drug launches
FDA
COVID-19
Zeposia
Flag link:
Janssen files MS pill, ahead of FDA decision on BMS’ rival
Janssen files MS pill, ahead of FDA decision on BMS’ rival
Pharmaforum
Janssen
JNJ
multiple sclerosis
MS
FDA
ponesimod
Bristol-Myers Squibb
ozanimod
Flag link:
France’s MedDay says drug for MS falls at phase 3 hurdle
France’s MedDay says drug for MS falls at phase 3 hurdle
Pharmaforum
MedDay Pharma
France
MD1003
multiple sclerosis
MS
clinical trials
Flag link:
Go or no go? Ozanimod and Fintepla await FDA verdicts
Go or no go? Ozanimod and Fintepla await FDA verdicts
EP Vantage
Bristol-Myers Squibb
ozaminod
MS
multiple sclerosis
Zogenix
Fintepla
FDA
Flag link:
Teva Calls on FDA to Make Copaxone a Biologic as Part of March Transition
Teva Calls on FDA to Make Copaxone a Biologic as Part of March Transition
RAPS.org
Teva Pharmaceutical
Copaxone
MS
multiple sclerosis
FDA
biologics
Flag link:
Novartis gets a boost in blockbuster multiple sclerosis race with Roche
Novartis gets a boost in blockbuster multiple sclerosis race with Roche
Endpoints
Novartis
MS
multiple sclerosis
FDA
priority reviews
Arzerra
Flag link:
To challenge Ocrevus, German Merck takes on Aubagio
To challenge Ocrevus, German Merck takes on Aubagio
EP Vantage
Ocrevus
Merck KGaA
Aubagio
evobrutinib
MS
multiple sclerosis
Flag link:
Will Biogen’s Big Patent Victory Ease Investor Worries About Its Alzheimer’s Drug?
Will Biogen’s Big Patent Victory Ease Investor Worries About Its Alzheimer’s Drug?
Motley Fool
Biogen
Mylan
Alzheimer's disease
patents
Tecfidera
MS
multiple sclerosis
Vumerity
Flag link:
Multiple Sclerosis Update: Biogen, Sanofi, Active, Adamas and Novartis
Multiple Sclerosis Update: Biogen, Sanofi, Active, Adamas and Novartis
BioSpace
MS
multiple sclerosis
Biogen
Sanofi
Active Biotech
Mylan
Novartis
Adamas
Flag link:
Multiple sclerosis “win” makes the Principia shorts squirm
Multiple sclerosis “win” makes the Principia shorts squirm
EP Vantage
Principia Biopharma
SAR442168
MS
multiple sclerosis
Flag link:

Pages